Advancement in medical treatment for gastrointestinal stromal tumors (GISTs): a ray of hope

被引：0

作者：

Singh, Harpreet ^{[1
]}

Mohanto, Sourav ^{[2
]}

Chopra, Hitesh ^{[3
]}

Chopra, Shivani ^{[4
]}

Mishra, Arun Kumar ^{[5
]}

Venkatachalam, T. ^{[6
]}

Bin Emran, Talha ^{[7
,8
]}

机构：

[1] IFTM Univ, Sch Pharmaceut Sci, Moradabad, India

[2] Yenepoya, Yenepoya Pharm Coll & Res Ctr, Dept Pharmaceut, Mangalore, India

[3] Chitkara Univ, Chitkara Coll Pharm, Ctr Res Impact & Outcome, Rajpura, India

[4] Saveetha Inst Med & Tech Sci, Saveetha Sch Engn, Dept Biosci, Chennai, India

[5] IFTM Univ, SOS Sch Pharm, Moradabad, India

[6] Tamil Nadu Dr MGR Med Univ, Dept Pharmaceut Chem, JKKMMRFs Annai JKK Sampoorani Ammal Collage Pharm, Namakkal, India

[7] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka, Bangladesh

[8] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong, Bangladesh

来源：

ANNALS OF MEDICINE AND SURGERY | 2025年 / 87卷 / 03期

关键词：

gastrointestinal stromal tumors; immunotherapy; molecular alterations; non-coding RNAs; predictive biomarkers; IMATINIB; METHYLATION; DIAGNOSIS; ADJUVANT; THERAPY;

D O I：

10.1097/MS9.0000000000002843

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Gastrointestinal stromal tumors (GISTs) present unique diagnostic and therapeutic challenges. This review highlights advancements facilitated by molecularly targeted therapies like imatinib for advanced, metastatic, and high-risk GISTs, underscoring their neoadjuvant/adjuvant utility and the importance of multidisciplinary care. Emerging avenues, including immunotherapy, PI3K/mTOR/HSP90 inhibitors, are examined, reflecting the evolving treatment landscape. Furthermore, it explores distinct clinical considerations for GIST subtypes like spindle cell, epithelioid, mixed, and SDH-deficient tumors. Crucially, identifying predictive biomarkers (molecular alterations, non-coding RNAs, SLITRK3 expression, aberrant DNA methylation, radiomics) is emphasized for optimizing individualized regimens and improving outcomes. Overall, the review highlights the remarkable advances in GIST treatment while emphasizing the need for ongoing research into novel, molecularly tailored therapeutic strategies.

引用

页码：1383 / 1393

页数：11

共 98 条

[1] Recent advances in the management of gastrointestinal stromal tumor [J].

Ahmed, Monjur .

WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (15) :3142-U30

[2] Staged surgical approach for metastatic GIST, how far should we go? Case report [J].

Alqattan, Abdullah Saleh ;

Ibrahim, Arwa Hanafie ;

Al Abdrabalnabi, Alaa A. ;

AlShahrani, Abdulwahab A. .

INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2021, 84

[3] Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors [J].

Amirnasr, Azadeh ;

Sleijfer, Stefan ;

Wiemer, Erik A. C. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (18) :1-23

[4]

[Anonymous], 2007, Study Details | Efficacy and Safety of Nilotinib (AMN107) Compared with Current Treatment Options in Patients with GIST Who Have Failed Both Imatinib and Sunitinib |

[5]

[Anonymous], 2016, Study Details | Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor

[6]

[Anonymous], 2010, Study Details | Everolimus in Combination with Imatinib in Patients with Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

[7]

[Anonymous], 2019, Study Details | Phase II Trial of Vandetanib in Children and Adults with Wild-Type Gastrointestinal Stromal Tumors |

[8]

[Anonymous], 2016, Study Details | Trial of Dasatinib in Advanced Sarcomas |

[9]

[Anonymous], 2012, Study Details | Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients with Primary or Recurrent Malignant Gastrointestinal Stromal Tumor |

[10]

[Anonymous], 2018, ClinicalTrials.gov

← 1 2 3 4 5 6 7 8 9 10 →